Development and validation of a fast and sensitive UHPLC-DAD assay for the quantification of nitrofurantoin in plasma and urine

Rixt A. Wijma, Karin E. J. Hoogtanders, Sander Croes, Johan W. Mouton, Roger J. M. Bruggemann*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Web of Science)

Abstract

Nitrofurantoin is an antimicrobial drug that has been used in the treatment of lower urinary tract infections for more than 50 years. Despite its long use, surprisingly little is known of the pharmacokinetics of nitrofurantoin, whereas this is essential to optimize patient treatment. We developed a novel analytical method for the quantification of nitrofurantoin in plasma and urine using ultra-high performance liquid chromatography and diode array detection to allow pharmacokinetic studies in these two matrices. The sample preparation method consisted of protein precipitation for plasma and liquid-liquid extraction for urine. 100 mu L was needed for the sample preparation. Furazolidone was used as internal standard. Gradient chromatographic separation was performed on a HSS-T3 column. UV detection was performed at a wavelength of 369 nm. The analysis time was 5 min. The method was successfully validated according to the FDA-guidelines (2018). Linearity was confirmed over a concentration range from 50 to 1250 mu g/L in plasma and from 4 to 200 mg/L in urine (r(2) > 0.95). Validation results of five QC concentrations for plasma and urine, respectively, are for within-day accuracy

Original languageEnglish
Pages (from-to)161-167
Number of pages7
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume174
DOIs
Publication statusPublished - 10 Sep 2019

Keywords

  • Nitrofurantoin
  • Pharmacokinetics/Pharmacodynamics
  • UHPLC-DAD
  • Antimicrobial drug
  • Urinary tract infections
  • LIQUID-CHROMATOGRAPHIC ASSAY
  • OLD ANTIBIOTICS
  • BIOAVAILABILITY
  • EPIDEMIOLOGY
  • QUANTITATION
  • FUTURE
  • FLUIDS
  • DRUGS

Cite this